Mohamed A. Kharfan‐Dabaja

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Michael R. Bishop, Michael Dickinson, Duncan Purtill et al. · New England Journal of Medicine · 2021 · 520 citations · Full text

Medicine, Hematology, Oncology +9

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

Abraham S. Kanate, Alberto Mussetti, Mohamed A. Kharfan‐Dabaja et al. · Blood · 2015 · 271 citations · Full text

Medicine, Hematology, Immunology +15

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

Mohamed A. Kharfan‐Dabaja, Michael Boeckh, Marissa B. Wilck et al. · The Lancet Infectious Diseases · 2012 · 230 citations · Full text

Medicine, Immunology, Infectious Diseases +16

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis

Nilanjan Ghosh, Reem Karmali, Vanderson Rocha et al. · Journal of Clinical Oncology · 2016 · 227 citations

Life Sciences, Hematology, Immunology +14

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

Nizar J. Bahlis, Jennifer McCafferty-Grad, Ileana Jordan-McMurry et al. · PubMed · 2002 · 190 citations

Medicine, Oncology, Pharmacology +15